US Patent

US11311620 — Neoadjuvant therapy for bladder cancer

Method of Use · Assigned to Photocure ASA · Expires 2036-12-19 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using hexaminolevulinate hydrochloride in a neoadjuvant therapy for bladder cancer patients scheduled for a cystectomy.

USPTO Abstract

This invention relates to a neoadjuvant therapy for bladder cancer in bladder cancer patients who are scheduled for a cystectomy and methods of carrying out such a neoadjuvant therapy. In particular, the invention relates to a composition comprising hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof for use in a neoadjuvant therapy for bladder cancer in a bladder cancer patient who is scheduled for a cystectomy, the therapy comprises instilling said composition into the bladder of said patient and exposing the inside of said bladder to light.

Drugs covered by this patent

hexaminolevulinate-hydrochloride (HEXAMINOLEVULINATE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2250`	—	hexaminolevulinate-hydrochloride

Patent Metadata

Patent number: US11311620
Jurisdiction: US
Classification: Method of Use
Expires: 2036-12-19
Drug substance claim: No
Drug product claim: No
Assignee: Photocure ASA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.